

A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus influenza vaccine to healthy young adults.

EudraCT Number: **2017-000116-42**

Version Number: **1.7**

Date: **18 JAN 2017**

Confidentiality Statement

The information contained in this document is the property of the Centre for Vaccinology (CEVAC), Ghent University and Ghent University Hospital and is provided to you in confidence as an investigator, potential investigator, sponsor, or consultant, for review by you, your staff and an applicable Ethics Committee (EC). It is understood that this information will not be disclosed to others without written authorisation from CEVAC (UGent/UZGent), except to the extent necessary to obtain written informed consent from those persons to whom the drug may be administered.

1 CLINICAL STUDY PROTOCOL AGREEMENT FORM

Authorisation of final version

A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus influenza vaccine to healthy young adults.

On behalf of the Sponsor: Ghent University Hospital – Center for Vaccinology
CEO UZGent

Signature Date

Name: Prof. Dr. E. MORTIER

Principal Investigator Agreement

I agree to conduct this study according to this protocol and to comply with its requirements, subject to ethical principles that have their origins in the Declaration of Helsinki, safety considerations and the applicable laws and regulations, I agree to conduct the study in accordance with local regulations and the International Conference on Harmonisation Topic E6: Guideline for Good Clinical Practice (ICH GCP).

I will promptly submit the protocol to applicable Ethical Review Board. I agree not to make any changes to the protocol without agreement from the sponsor and prior review and written approval from the local Ethical Review Board, except where necessary to halt an immediate threat to subject safety, or for administrative study details when such actions are permitted by local regulations.

I understand fully the appropriate use of α -RIX-Tetra[®] as described in this protocol, and any other relevant material made available by the sponsor.

I will make certain that all personnel assisting with the study will be adequately informed about the study medication and their study-related duties as described in the protocol.

I understand that, should the decision be made by the Sponsor to terminate prematurely or suspend the study, at any time and for whatever reason, such decision will be communicated to me in writing. Conversely, should I decide to withdraw from execution of the study, I will communicate immediately in writing to the Sponsor or their representatives.

Principal Investigator – Director CEVAC

Signature 

Date 18 JAN 2017

Name: Prof. Dr. Geert LEROUX-ROELS

2 TABLE OF CONTENTS

1	CLINICAL STUDY PROTOCOL AGREEMENT FORM.....	2
2	TABLE OF CONTENTS	3
3	LIST OF ABBREVIATIONS AND DEFINITIONS.....	5
4	CONTACT INFORMATION	6
5	PROTOCOL SYNOPSIS	8
6	STUDY PROCEDURES FLOW CHART	12
7	SUMMARY OF STUDY DESIGN AND RATIONALE.....	13
	7.1 Introduction and Study Rationale.....	13
	7.2 Summary of Study Design.....	16
	7.3 Profile of Study Drugs.....	17
	7.4 Potential Risks and Benefits	17
	7.5 Rationale For Study Design.....	17
	7.5.1 Rationale for Doses	17
	7.5.2 Rationale for Exploratory Study Endpoints	17
	7.5.3 Blinding	18
8	STUDY OBJECTIVES AND ENDPOINTS	18
	8.1 Exploratory Study Objectives.....	18
	8.2 Study Endpoints (study variables measured).....	19
9	SUBJECT SELECTION AND WITHDRAWAL CRITERIA	19
	9.1 Population base.....	19
	9.2 Inclusion criteria	20
	9.3 Exclusion criteria.....	20
	9.4 Discontinuation and Withdrawal of subjects from the study	21
10	CLINICAL STUDY PROTOCOL	22
	10.1 Study Procedures	22
	10.2 Duration of Study Participation.....	22
	10.3 Study Restrictions: prohibited vaccination and medication	22
11	STUDY MEDICATION	22
	11.1 Treatment Plan.....	22
	11.2 Preparation, Administration and Dosage of Study Medication.....	23
	11.2.1 Preparation Instructions.....	23
	11.2.2 Route of administration	23
	11.2.3 Dose and Dosing Schedule	23
	11.3 Packaging and Labelling	23
	11.4 Storage and Accountability of Drug Supplies	23
	11.5 Destruction of Clinical Supplies.....	23
	11.6 Responsibilities.....	23
	11.7 Compliance.....	23
	11.8 Treatment Assignment Procedures.....	24
12	STUDY DATA PARAMETERS	24
	12.1 Laboratory Assessments.....	24
	12.1.1 Study Blood Volume	25
	12.1.2 Urinalysis.....	25
	12.1.3 Urine pregnancy test.....	25
	12.2 Vital signs.....	25

12.3	Measurement of temperature and injection site reactions	25
12.4	Methods and Timing for Assessing and Recording Study Data Parameters	25
13	SAFETY MONITORING	26
13.1	Specification of Safety Parameters	26
13.1.1	Laboratory and Other Safety Assessment Abnormalities Reported as AEs and SAEs	26
13.1.2	Definition of an AE	26
13.1.3	Definition of a SAE	27
13.2	Evaluating and Recording (Serious) Adverse Events.....	27
13.3	Intensity of Event	28
13.4	Relationship to study product	29
13.5	Expectedness of SAEs	30
13.6	Reporting of serious adverse events, pregnancies, and other events.....	30
14	STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN	31
14.1	Responsibility for Analysis	31
14.2	Justification of Sample Size	31
14.3	Definition of Study Completion	31
14.4	Definition of Criteria for Termination of the Study	31
14.5	Analysis of Clinical Events and Exploratory Endpoints after immunisation	31
15	STUDY DOCUMENTATION ADMINISTRATION	32
15.1	Source documents and eCRF	32
15.2	Monitoring	32
15.3	Access to Source Data Documents	32
15.4	Data Handling and Record Retention	33
15.5	Subject Confidentiality and Data Protection	33
16	QUALITY CONTROL AND QUALITY ASSURANCE	33
17	CLINICAL STUDY PROTOCOL DEVIATIONS AND AMENDMENTS	33
18	CONDITIONS FOR TERMINATING THE STUDY	34
19	ETHICAL AND REGULATORY REQUIREMENTS	34
19.1	Informed Consent	34
19.2	Independent Ethics Committee (IEC).....	34
19.3	Final Reports	35
20	FINANCE AND INSURANCE	35
21	PUBLICATIONS	35
22	REFERENCES	35
23	Laboratory Safety Analysis	36
24	Exploratory analyses.....	36

3 LIST OF ABBREVIATIONS AND DEFINITIONS

AE	Adverse Event
Bimetra	Clinical Research Center Ghent
BMI	Body Mass Index
BP	Blood Pressure
CBC	Complete Blood Count
CEVAC	Centre for Vaccinology Ghent
CMI	Cell Mediated Immunity
CRF	Case Report Form
EC	Ethics Committee
ESR	Erythrocyte Sedimentation Rate
FBC	Full Blood Count
GCP	Good Clinical Practice
HA	Haemagglutinin
HAI	Haemagglutination Inhibition
ICF	Informed Consent Form
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IM	Intramuscular
PBMC	Peripheral Blood Mononuclear Cells
PI	Principal Investigator
QIV	Quadrivalent inactivated influenza vaccine
SAE	Serious Adverse Event
SC	Subcutaneous
SmPC	Summary of Product Characteristics
SOPs	Standard Operating Procedures
WBC	White Blood Cells

4 CONTACT INFORMATION

**PRINCIPAL
INVESTIGATOR**

Name: Geert Leroux-Roels, MD, PhD
Address: CEVAC, De Pintelaan 185, 9000 Gent, Belgium
Tel: +32 9 332 21 23
Fax: +32 9 332 22 85
Email: Geert.LerouxRoels@ugent.be

**Principal Clinical
Research Physicians**

Name: Cathy Maes, MD
Address: CEVAC, De Pintelaan 185, 9000 Gent, Belgium
Tel: +32 9 332 94 65
Fax: +32 9 332 22 85
Email: Cathy.Maes@uzgent.be

Name: Annelies Aerssens, MD
Address: CEVAC, De Pintelaan 185, 9000 Gent, Belgium
Tel: +32 9 332 00 72
Fax: +32 9 332 22 85
Email: Annelies.Aerssens@uzgent.be

Name: Isabel Leroux-Roels, MD, PhD
Address: CEVAC, De Pintelaan 185, 9000 Gent, Belgium
Tel: +32 9 332 33 28
Fax: +32 9 332 22 85
Email: Isabel.Lerouxroels@uzgent.be

**Clinical Research
Coordinator**

Name: Fien De Boever, MSc
Address: CEVAC, De Pintelaan 185, 9000 Gent, Belgium
Tel: +32 9 332 34 93
Fax: +32 9 332 22 85
Email: Fien.DeBoever@uzgent.be

**COLLABORATING
LABORATORIES**

Laboratorium voor klinische biologie
Universitair Ziekenhuis Gent
De Pintelaan 185
9000 Gent – Belgium
Contact: Prof. G. Leroux-Roels
Tel: +32 9 332 21 23
Fax: +32 9 332 63 11
Email: geert.lerouxroels@ugent.be

CEVAC Core Lab
Universiteit Gent
De Pintelaan 185
9000 Gent – Belgium
Contact: Frederic Clement
Tel: +32 9 332 36 54

Fax: +32 9 332 63 11
Email: Frederic.Clement@ugent.be

Max Planck Institute for
Infection Biology (MPIIB)
Department for Immunology
Chariteplatz 1
10117 Berlin
Germany
Contact person: Dr Gayle McEwen
Email: mcewen@mpiib-berlin.mpg.de

deCODE genetics
Sturlugata 8, Reykjavik
IS-101 Iceland
Contact: Ingileif Jónsdóttir
Email: Ingileif.Jonsdottir@decode.is

VisMederi srl
Via Fiorentina 1
53100 SIENA-ITALY
Contact: Prof E. Montomoli
Tel: +39-0577231253
Fax: +39-057743444
Email: emanuele.montomoli@unisi.it
vismederi@pec.it

Other laboratories and Biovacsafe collaborators may be used for the analysis of other laboratory parameters.

5 PROTOCOL SYNOPSIS

Title	A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus influenza vaccine to healthy young adults
Sponsor	Ghent University Hospital – Center for Vaccinology
EudraCT Number	2017-000116-42
Principal Investigator	Geert Leroux-Roels, MD, PhD
Study Location	CEVAC - Ghent University and Ghent University Hospital
Indication	Biomarkers of vaccine safety and immunogenicity
Study Objectives	<ul style="list-style-type: none"> • To characterise clinical symptoms after the administration of a single dose of quadrivalent inactivated split virus influenza vaccine • To determine and quantify changes in innate and adaptive immune responses to influenza antigens • To identify biomarkers that predict clinical symptoms and associate with innate and adaptive immune responses • To compare the data generated during this clinical vaccine trial, namely the clinical, biochemical and immunological changes induced by vaccine administration with those generated during an influenza virus challenge study conducted in Imperial College London in a comparable cohort of healthy young adults. <i>This comparison may provide a basis for the validation of the BioVacSafe Data Standards Package and Adverse Events Signal Detection tools.</i> <p>The data set will include data characterising:</p> <ol style="list-style-type: none"> 1. Physiological responses at various time points after immunisation by measuring: <ol style="list-style-type: none"> a. Local and systemic vaccine-related clinical events. b. Physiological assessments: heart rate, temperature, blood pressure. c. Haematology (complete blood counts (CBC), erythrocyte sedimentation rate (ESR) and phenotyping of white blood cells (WBC)) and biochemistry parameters. 2. Innate and adaptive immune responses including: <ol style="list-style-type: none"> a. Innate immune activation detected by global gene expression in whole blood b. Adaptive immunity determined by

	<ul style="list-style-type: none"> i. Humoral immune response to QIV via serum anti-influenza HAI titre ii. Cellular immune response to influenza antigens c. Immune activation detected by: <ul style="list-style-type: none"> i. Concentration of selected inflammatory soluble mediators in serum including: <ul style="list-style-type: none"> 1. chemokines and cytokines 2. acute phase proteins ii. PBMC cytokine secretion, proliferation or surface marker expression in response to <i>in vitro</i> antigen stimulation. 3. Genetic testing of subjects when deemed necessary (genetic testing analysis may be SNIP analysis or full genome analysis). 4. Correlations between changes in innate immune activation and adverse events, haematology and biochemistry panels, genotype and physiological assessments 5. Correlations between changes in innate immune activation and adaptive immune responses (humoral and/or cellular)
Study Design	Open-label, non-randomised, not-controlled monocentric study
Population	20 healthy adults
Main Selection Criteria	<ul style="list-style-type: none"> • Age: 24-54 years • Intended target for man:woman 1:1 ratio • Healthy: no active disease process that could interfere with endpoints measured as determined by medical history • Not taking regular medications that could interfere with endpoints measured • No contraindications to α-RIX-Tetra[®] vaccine • No history of influenza infection in the past 5 years (defined here as severe respiratory infection with fever (> 38°C) and preventing normal daily activity during a minimum of 3 days) • No administration of any influenza vaccine in the past 5 years
Study Medicinal Products: Formulations Route of Administration Dose regimen	All participants will receive <ul style="list-style-type: none"> • α-RIX-Tetra[®], a quadrivalent inactivated split virus influenza vaccine for season 2016-2017 (Northern Hemisphere) • Single 0.5 mL dose

	<ul style="list-style-type: none"> • Intramuscular, deltoid muscle • One injection on one occasion
Concurrent Controls	None - each subject acts as their own control from baseline values
Exploratory Study Endpoints (study variables measured)	<ol style="list-style-type: none"> 1. Frequency of local and systemic vaccine-related clinical events at all time points from vaccination up to last study visit. 2. Change from pre-immunisation baseline values in pulse, temperature and blood pressure at all time points from time of immunisation up to last study visit. 3. Change from pre-immunisation baseline values in haematology (CBC, ESR, phenotyping of WBC), biochemistry (liver, renal and metabolism) parameters at selected time points from time of immunisation up to last study visit. 4. PAXgene™ tubes drawn to evaluate change from pre-immunisation baseline values in global gene expression measured on whole blood samples at selected time points from time of immunisation up to last study visit 5. Change from pre-immunisation baseline values and fold increase in serum HAI titre against all four vaccine strains in serum samples at selected time points from time of immunisation up to last study visit. 6. Change from pre-immunisation values of adaptive cellular immune response will be evaluated at selected time points in all subjects via enumeration of HA-specific CD4⁺ and CD8⁺ T cells expressing activation markers and/or cytokines by flow cytometry following <i>in vitro</i> stimulation with split antigen derived from each of the four vaccine strains and wherever possible with purified HA protein or overlapping peptides representing HA. 7. Change from pre-immunisation baseline values in PBMC cytokine secretion in response to <i>in vitro</i> stimulation with aforementioned antigen(s) at selected time points from time of immunisation up to last study visit 8. Examine correlations between changes of innate immune activation and occurrence and magnitude of adverse events, haematology and biochemistry panels, genotype and physiological assessments 9. Examine correlations between pre-existing humoral and/or cellular immunity and occurrence and severity of local or general adverse events 10. Examine correlations between changes of innate immune activation and magnitude of adaptive immune responses (humoral and/or cellular)

Assessment Schedule	<p>Screening and Immunisation Visit (Day 0)</p> <ul style="list-style-type: none"> • Informed Consent • Demography • Medical history and concomitant medication • Assessment of inclusion/exclusion criteria • Height, weight, BMI • Vital signs (blood pressure, heart rate, oral temperature) • Physical examination • Urine pregnancy test (only in female participants of childbearing potential) • Clinical samples as per Table 1 (Study Procedures Flow Chart) • Vaccine administration • (S)AEs recorded <p>Follow Up Visits (Day 1, Day 2, Day 3, Day 7, Day 14 and Day 28)</p> <ul style="list-style-type: none"> • Vital signs (blood pressure, heart rate, oral temperature) • Continued eligibility check • Concomitant medications • Clinical samples as per Table 1 (Study Procedures Flow Chart) (S)AEs recorded
Data Analysis	Exploratory endpoints will be analysed by a Systems Biology approach to identify exploratory biomarkers, the statistical analysis plan will be developed by the BioVacSafe consortium
Duration of Study Period (per subject)	28 days

6 STUDY PROCEDURES FLOW CHART

Table 1: Study Procedures Flow Chart

Visit Name	Visit 1 Day 0	Visit 2 Day 1	Visit 3 Day 2	Visit 4 Day 3	Visit 5 Day 7	Visit 6 Day 14	Visit 7 Day 28
Procedures							
Written informed consent	X						
Demographic data	X						
Physical exam	X						
Medical history	X						
Concomitant medication	X	X	X	X	X	X	X
Vital signs ^a	X	X	X	X	X	X	X
Laboratory safety, blood and urine ^b	X	X	X	X	X		
Screening serology (hepatitis B and C, HIV)	X						
Pregnancy Test: Urine ^c	X						
Vaccine administration	X						
Whole blood for PBMC isolation ^d	X	X			X	X	
PAXgene tube	X	X	X	X			
Serum ^d	X	X	X	X	X	X	X
Plasma ^{d,e}	X	X	X	X			
Recording of (serious) adverse events after immunisation	X	X	X	X	X	X	X

^a Heart rate, blood pressure, oral temperature

^b Laboratory safety as detailed in section 23

^c Female subjects of childbearing potential only

^d Isolated PBMC, serum and plasma will be bio-banked and made available for further read-outs

^e blood collection tubes with citrate as anticoagulant


7 SUMMARY OF STUDY DESIGN AND RATIONALE

7.1 Introduction and Study Rationale

Currently licensed vaccines are widely accepted to be safe and to have an acceptable reactogenicity profile. Vaccine development lead-times are extremely long and expensive due to the requirements for the extensive safety and efficacy testing required prior to Market Authorization. Rarely, significant adverse reactions have been detected post-licensure that were not detected during the development of the vaccine and only became apparent during large-scale Phase IV post marketing surveillance (e.g. intussusception, Bell's palsy). Such events have led to the withdrawal of vaccines from the market, resulting in financial impact, loss of confidence in vaccines, and individual harm to those affected and potentially to those exposed to vaccine-preventable diseases by decreases in immunization rates.

Clinical trials during the early stage pre-marketing assessment of safety and efficacy are not designed or powered to study immunopathological responses intensively enough to detect *transient* or *infrequent* phenomena (e.g. auto-reactive B and T cells, inflammation), or in sufficient *depth* (frequency of sampling, application of advanced technology) to be able to predict rare or subtle events which, in susceptible recipients, may subsequently trigger or lead to exacerbation of autoimmune or inflammatory diseases.

Vaccines are thought to trigger innate inflammatory responses to induce antigen-specific adaptive immunity (the desired effect of a vaccine), but excessive inflammation may lead to serious inflammatory complications or unwanted side effects. A lack of reliable biomarkers predicting severe inflammation has halted several exploratory vaccines, and withdrawn some licensed vaccines, some of which were associated with inflammatory complications, albeit low frequency, in some individuals. The BIOVACSAFE project, a 5-year €30M project funded by the Innovative Medicine Initiative, has undertaken a **series of correlated clinical studies** with the aim to generate *clinical* data on inflammation with licensed vaccines as benchmarks, and to identify biomarkers to predict acceptable reactogenicity, for correlation with standardized clinical readouts and inflammatory markers assessed in natural infections.



The overall project followed the general structure of three studies employing five different vaccines plus placebo groups that generated a biobank of samples and a set of data (clinical responses, gene responses, proteins and immunology responses). Apart from using different vaccines, each study followed the same protocol to allow the data

to be combined into one dataset and biobank. Integrated systems biology analysis of the data and iterative access to the biobank, will identify putative “biomarkers” of inflammation.

Following these studies, two larger clinical trials were conducted in CEVAC (Ghent University and Ghent University Hospital) to confirm or refute the validity of these putative biomarkers. These “confirmatory trials” were added to the database and biobank to allow further rounds of integrated systems biology analysis to generate hypotheses and putative biomarkers for future research projects. The scheme is illustrated in the diagram above.

The combination of studying basic responses at the protein, gene and metabolic level is often termed “biomics”. Biomics can be exploited to discover **biomarkers** (a measurable biological response that predicts something), which may be useful for monitoring of vaccine trials, and ideally can predict occurrence of beneficial and detrimental effects that are directly correlated with side effects and efficacy of vaccines undergoing clinical testing in humans. The different biomics include transcriptomics (genes), metabolomics (lipids and metabolites) and proteomics (proteins). In this project transcriptomics and metabolomics, together with profiling of cytokines and chemokines (molecules produced in immune responses) will be harnessed for assessment of vaccine responses with an emphasis on immunosafety and immunogenicity. Global gene expression profiling by transcriptomics has led to the definition of biosignatures, which can be used to discriminate diseased from healthy individuals. More recently, such studies have also been exploited for monitoring of vaccine effects in vaccinees (Pulendran et al., 2010).

Blood transcriptional profiles reflect the immune status of the host and expression patterns change upon infection and early inflammation. Cytokine profiles are linked to the blood transcriptome because they are, in part, influenced by leukocyte gene expression, but contain additional information resulting from processes occurring in extra-vascular tissues. Metabolomics identifies and quantifies small molecules to provide insights into changes in general metabolomic processes, while multiplex cytokine/chemokine profiling provides a “batch immune answer” of inflammatory processes. Both of these platforms complement transcriptomics and are known to be good predictors for disease and/or inflammation, underlining their relevance to vaccine safety. The technologies used in this clinical study are integrated with other technologies to deliver state of the art biomics and systems biology analysis for an integrated set of Clinical Studies (parallel studies using the same vaccines in animal models), and related population-based studies of infections and allergy. The clinical studies of which this is one will closely integrate with other activities within the BIOVACSAFE project to translate biomarker discovery into practical tools for vaccine development and regulation.

The characterization of early innate immune system events following immunization (days 0-3, 7-30) by gene expression and multiplex cytokine/cellular response analysis (systems biology approach) have been used to successfully identify biomarkers of inflammation and immune response/efficacy. This has been done in a predictive and reproducible way by immunizing relatively small numbers of healthy subjects, for example with live viral Yellow Fever vaccine (Querec et al., 2009) or adjuvanted subunit malaria vaccines (Vahey et al., 2010). This opens-up the novel possibility to conduct intensive and highly focused, but relatively small clinical trials early-on in the

development of novel vaccine technologies to identify biomarkers that may be predictive of safety signals that may only become apparent in subsequent larger scale clinical testing or during post marketing surveillance.

We propose to apply a systems biology approach to identify predictive biomarkers of vaccine immunosafety in the context of an initial “Training Study” that incorporate intensive clinical monitoring of vaccine recipients, standardized Adverse Event definitions, accepted measurements of immune responses and in which the analytic plan will strive to correlate biomarker activity with observed physiological and immunological responses to vaccination. In addition, while studies of transcriptomics or other biomics technologies have been used in previous studies, we will for the first time bring together metabolomics, transcriptomics and other biomics technologies, together with readouts of immune-efficacy and standardized definitions of adverse reactions, to the simultaneous evaluation relevant licensed vaccines studied under a highly standardized clinical setting to assess the relationships between these biomarkers and the short term reactogenicity of, and immune responses to, the selected vaccines. We will, in particular, use detailed metabolic models to link transcription data with metabolomics data and hereby potentially improve the statistical power in terms of biomarker identification. If successful, these biomarkers could be used in early stage clinical trials to optimize selection of vaccine candidates with a profile that will be unlikely to generate worrisome safety signals once they are in generalized use.

An important feature of the BIOVACSAFE project is the fact that studies were restricted to licensed vaccines which are accepted by regulatory authorities as being safe, well tolerated, and sufficiently efficacious to warrant their recommendation for general use. We do not have access to vaccines that have been shown in pre- or post-marketing studies to be unsafe or non-efficacious. Thus, the conclusions that can be drawn from these studies must be understood in the context of the null hypothesis that vaccines having the biomarker profiles identified in these studies do not present a potential safety risk for the general population. This does not mean that in certain genetically predisposed individuals, or in persons with active underlying autoimmune disease, these vaccines could potentially trigger or exacerbate autoimmune disease.

In the past year (2013-2014) intense training studies have been conducted, involving groups of 20 subjects randomized per vaccine treatment group, with matched male: female ratio. Subjects in the placebo groups of each of these studies have been pooled to give a placebo group size of at least 20. Consideration will be given in the analysis to the different routes of immunisation (SC and IM). In addition, each subject acts as their own control for kinetics with comparison from the baseline pre-immunisation levels of biomarkers measured.

Due to the large numbers of individual samples generated across the proposed time course of monitoring, and restrictions on budget, we will biobank all samples at all time points measured. Subsequently, in collaboration with parallel studies in animal models and based on the observed clinical signs and symptoms for each vaccine, analysis of selected time points will be undertaken for all subjects to identify biomarkers. In a subset of subjects the full time course will be analysed to generate kinetics, based on the reactogenicity observed. All selection processes will involve the External Advisory Board of the BIOVACSAFE project who are international experts in the field of Systems Biology and vaccine safety. Where certain post immunization events are recorded (e.g. fever, injection site reaction) a full time course analysis across the event

will be analysed within those subjects, acting as their own controls. Biomarkers that are significant according to previously published criteria for gene expression (e.g. Pulendran et al., 2010) will be selected for advancing into the animal models WP2, and into later stage clinical confirmatory trials.

With the experience acquired during the exploratory trials conducted at the University of Surrey, two larger confirmatory trials have been conducted at the Center for Vaccinology, Ghent University and University Hospital. In parallel numerous studies have been conducted in animal models. The host of information gathered during these studies and the wealth of samples collected are now being analysed.

The present clinical study using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that will use a challenge with live virus as intervention. Comparison of the clinical observations and laboratory measurements generated in both studies will inform us about the similarities and differences in innate and adaptive immune responses elicited by both types of exposure to influenza virus antigen(s).

7.2 Summary of Study Design

α -RIX-Tetra[®] is a quadrivalent inactivated split virus influenza vaccine for season 2016-2017 (Northern Hemisphere), and it will be given to a population of healthy adults, aged 24 to 54 years, that has had no episode of an influenza infection nor the administration of an influenza vaccine in the past 5 years. Efforts will be made for a man:woman 1:1 ratio.

The study is a monocentric, open label study.

All subjects will receive a single dose of the vaccine at the recommended dose level according to the SmPC. The following will be measured - clinical events (recorded adverse events), physiological responses (heart rate, blood pressure, temperature, injection site), innate immune responses (cytokine levels and whole blood gene expression) and adaptive immune responses (serum antibody and antigen-specific cellular responses) at various time points after immunisation.

At each study visit, full physiological parameters (including body temperature, heart rate, blood pressure) will be obtained and the injection site will be examined for the presence of any redness or swelling that will be measured and recorded. Standardized diary cards will be used to collect solicited and unsolicited clinical event data. At each visit the diary cards will be examined and any relevant clinical event will be entered into the clinical event form. Participants will be asked to monitor oral temperature from day 0 until day 7 when they wake up and when going to bed. The results of these measurements will be reported in a diary card. Any skin reactions at the site of injection will be evaluated; largest diameter of redness and swelling will be measured with a ruler and data reported on the diary card. Samples of blood (PAXgene tubes, plasma, serum and PBMCs) will be collected for analysis and processing using protocols already in place. Subjects will also have blood obtained for standard safety markers (haematology, biochemistry) as well as acute phase proteins.

7.3 Profile of Study Drugs

α -RIX-Tetra[®] – a quadrivalent inactivated split virus influenza vaccine as produced and distributed for the 2016/2017 Northern Hemisphere influenza season.

7.4 Potential Risks and Benefits

Please refer to the SmPCs. The α -RIX-Tetra[®] vaccine will be administered as an intramuscular injection of 0.5 mL in the upper arm (deltoid region of the non-dominant arm) according to the SmPCs with the following exceptions:

α -RIX-Tetra[®] The SmPC details that α -RIX-Tetra[®] is a quadrivalent, inactivated split virus influenza virus vaccine. It is indicated for active immunization against influenza in adults and children from 3 years of age onwards. α -RIX-Tetra[®] is contraindicated in individuals with a known hypersensitivity to the active components, any of the excipients (disodium phosphate dodecahydrate, potassium dihydrogen phosphate, magnesium chloride hexahydrate, α -tocopheryl hydrogen succinate, polysorbate 80, octoxinol 10), eggs (chicken proteins, ovalbumin), gentamycin sulphate, formaldehyde, and sodium deoxycholate or those who have had a previous life-threatening reaction to previous influenza vaccinations. The most common local adverse drug reaction is injection site pain.

7.5 Rationale For Study Design

7.5.1 Rationale for Doses

The study will use the dose of α -RIX-Tetra[®] indicated in the SmPC as the purpose of this study is to characterise clinical events, physiological and metabolic responses, and innate and adaptive immune responses following immunisation with products used in accordance with the SmPC.

7.5.2 Rationale for Exploratory Study Endpoints

The characterisation of early immune response events following immunization (days 0-3, and 7 by gene expression and multiplex cytokine/cellular response analysis systems biology approach) have been used to successfully identify biomarkers of inflammation and immune response/efficacy. This has been done in a predictive and reproducible way by immunizing relatively small numbers of healthy subjects, for example with live viral Yellow Fever vaccine (Querec et al. 2009 Jan) or adjuvanted subunit malaria vaccines (Vahey et al., 2010). This opens up the novel possibility to conduct intensive and highly focused, but relatively small clinical trials early-on in the development of novel vaccine technologies to identify biomarkers that may be predictive of safety signals that may only become apparent in subsequent larger scale clinical testing or during post marketing surveillance. Since then two larger studies have been conducted to evaluate similar early inflammatory (innate) and adaptive immune responses following administration of one dose of adjuvanted influenza vaccine (FLUADTM) in one study involving 240 participants and one dose of dtPa vaccine (BOOSTRIX[®]) in another study involving 240 volunteers. Data of these studies are being analysed.

Serum will be used to measure a series of biochemical markers (acute phase proteins, cytokines, chemokines, ...) of vaccine safety and to quantify the magnitude of the specific antibody responses to the vaccine strains of the quadrivalent vaccine, measured as HAI titres.

Isolated PBMC will be used in the first place to investigate the adaptive immune responses following vaccination with one dose of the quadrivalent influenza vaccine.

The inflammatory (innate) and adaptive immune responses following vaccination with one dose of the quadrivalent influenza vaccine will be compared with those following an influenza infection induced by challenging healthy adult volunteers with a well characterized infectious influenza virus inoculum.

Isolated PBMC will be available for genetic testing in case specific biomarkers or clinical events be recorded, that require analysis of the DNA for genetic markers to identify new variants associated with responses to vaccines.

All samples will be link-anonymised and no genetic data will be made available to subjects or their medical attendants. It is unlikely that even a sample size of 200 subjects will be able to identify rare variants, but as vaccine reactogenicity is not infrequent (up to 30% may experience some side effects) we may identify common traits. Also our biobank will provide a highly characterised set of samples to undertake future research should larger studies identify genetic traits associated with reactogenicity.

7.5.3 *Blinding*

There is no blinding in this study. All participants will receive the same quadrivalent inactivated influenza vaccine (QIV).

8 **STUDY OBJECTIVES AND ENDPOINTS**

8.1 **Exploratory Study Objectives**

The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models. The dataset will broadly characterise:

1. Physiological responses at various time points after immunisation by measuring:
 - a. Local and systemic vaccine-related clinical events.
 - b. Physiological assessments: heart rate, body temperature, blood pressure.
 - c. Haematology (CBC, ESR, phenotyping of WBC), biochemistry parameters.
2. Innate and adaptive immune responses including:
 - a. Innate immune activation detected by global gene expression in whole blood
 - b. Adaptive immunity determined by:
 - i. Humoral immune response via serum anti-influenza HAI titre
 - ii. Cellular immune response
 - c. Immune activation detected by concentration of selected inflammatory soluble mediators in serum including:
 - i. chemokines and cytokines
 - ii. acute phase proteins
3. Genetic testing of subjects when deemed necessary (genetic testing analysis may be SNIP analysis or full genome analysis).

4. Correlations in changes in innate and adaptive immune activation with adverse events, haematology and biochemistry panels, genotype and physiological assessments

We will biobank all samples for the duration of the BIOVACSAFE programme so that we can selectively analyse different samples and different time points depending on the results generated, principally from the gene expression analysis of whole blood.

8.2 Study Endpoints (study variables measured)

The data set will include numerous study variables that will be analysed by integrated systems biology approach. Not all samples and not all time points will be initially analysed: an iterative approach is followed whereby putative biomarkers that are identified (principally in the gene expression data) will be further studied by measuring correlated variables such as immune responses, clinical events or serum / cellular responses. Samples will be biobanked during the project duration to allow further analyses that may be initiated by observations from the linked clinical studies. Once the study objectives have been achieved samples will either be destroyed, entered into a registered biobank, or ethical approval sought for subsequent use.

The study variables will include:

1. Frequency and severity of local and systemic vaccine-related clinical events at all time points from vaccination up to last study visit.
2. Change from pre-immunisation baseline values in pulse, temperature, blood pressure at all time points from time of immunisation up to last study visit.
3. Change from pre-immunisation baseline values in haematology (CBC, ESR, phenotyping of WBC), biochemistry parameters at selected time points from time of immunisation up to last study visit.
4. Change from pre-immunisation baseline values in global gene expression measured on whole blood samples at selected time points from time of immunisation up to last study visit
5. Change from pre-immunisation baseline values in serum HAI titre in serum samples at selected time points from time of immunisation up to last study visit
6. Change from pre-immunisation values of adaptive cellular immune response will be evaluated at selected time points in all subjects via enumeration of influenza-specific CD4⁺ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry.
7. Change from pre-immunisation baseline values in concentration of selected cytokines and acute phase proteins in serum samples at selected time points from time of immunisation up to last study visit
8. Change from pre-immunisation baseline values in PBMC cytokine secretion, proliferation or surface markers in response to in vitro stimulation with influenza antigens at selected time points from time of immunisation up to last study visit

9 SUBJECT SELECTION AND WITHDRAWAL CRITERIA

9.1 Population base

Twenty healthy male and female volunteers aged between 24 and 54 years.

9.2 Inclusion criteria

1. Healthy male or female subjects aged 24-54 years inclusive. (Healthy in the opinion of the investigator, based on medical history and clinical exam, with no active disease process that could interfere with the study endpoints)
2. Has a body Mass Index ≥ 18 and ≤ 30
3. Is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
4. The subject has signed the ICF.
5. The subject is available for follow-up for the duration of the study.
6. The subject agrees to abstain from donating blood during their participation in the study, or longer if necessary.
7. If the subject is a heterosexually active female, she is willing to use an effective method of contraception (e.g. oral contraceptive pill; intrauterine device; injectable or implanted contraceptive; physiological or anatomical sterility) from 30 days prior to study vaccination until the end of the study.
8. Willing to undergo urine pregnancy tests prior to vaccination at screening.
9. The subject has venous access sufficient to allow blood sampling as per the protocol.

9.3 Exclusion criteria

1. Pregnant or lactating.
2. Known hypersensitivity to any component of the study vaccine (α -RIX-Tetra[®]): the active components (vaccine antigens) or any of the excipients (disodium phosphate dodecahydrate, potassium dihydrogen phosphate, magnesium chloride hexahydrate, α -tocopheryl hydrogen succinate, polysorbate 80, octoxinol 10), eggs (chicken proteins, ovalbumin), gentamycin sulphate, formaldehyde, and sodium deoxycholate or those who have had a previous life-threatening reaction to previous influenza vaccinations.
3. History of influenza infection in the past 5 years, defined here as severe respiratory infection with fever ($> 38^{\circ}\text{C}$) and preventing normal daily activity during a minimum of 3 days.
4. Vaccination with the 2016/2017 seasonal influenza vaccine and/or any other seasonal influenza vaccine within the preceding 5 influenza seasons (i.e. since season 2011/2012) before the first study visit.
5. Presence of primary or acquired immunodeficiency states with a total lymphocyte count less than $1,200$ per mm^3 or presenting other evidence of lack of cellular immune competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving immunosuppressive therapy (including use of oral or parenteral corticosteroids in a dose ≥ 5 mg prednisone daily or equivalent within one month prior to visit 1 or cytotoxic or immunosuppressive or immunomodulating drugs within 6 months prior to visit 1).
6. Regular use of non-steroidal anti-inflammatory drugs (oral or parenteral route) within 6 months of Visit 1 considered by the study physician as likely to interfere with immune responses.
7. Current intake of excessive amounts of alcohol (≥ 14 units for women and ≥ 21 units for men) and not willing to adapt this use during the study period.

8. Currently performing extreme physical activities (as evaluated by the investigator) and not willing to adapt this activity during the study period.
9. Receipt of a vaccine within 30 days of visit 1, or requirement to receive another vaccine within the study period.
10. Presence of an acute severe febrile illness at time of immunisation.
11. History of alcohol, narcotic, benzodiazepine, rilatine, or other substance abuse or dependence within the 12 months preceding Visit 1.
12. Smoking in the past 6 months OR > 5 pack-year lifetime history
13. Receipt of blood products or immunoglobulins, or blood donation, within 3 months of study start.
14. Any condition that, in the investigator's opinion, compromises the subject's ability to meet protocol requirements or to complete the study.
15. Currently participating in another clinical study with an investigational or non-investigational drug or device, or has participated in a clinical trial within the 3 months preceding Visit 1.
16. Unable to read and speak Dutch or English to a fluency level adequate for the full comprehension of procedures required in participation and consent.

No waivers from the Protocol will be allowed.

9.4 Discontinuation and Withdrawal of subjects from the study

A subject may voluntarily discontinue participation in this study at any time.

The investigator may also, at his or her discretion, remove the subject from the study at any time, and must do so if any of the following criteria are met:

- Pregnancy at any time during the study.
- Concomitant use of any medication that may interfere with study outcome and study medication throughout the study.

The reason for termination will be recorded in the source notes and electronic case report form (eCRF). A subject may withdraw (or be withdrawn) from the study prematurely for the following reasons:

- Withdrawal of consent
- Adverse event (AE section must be completed)
- Protocol deviation
- Lost to follow-up
- Other (must be specified)

10 CLINICAL STUDY PROTOCOL

All 20 participants will undergo seven outpatient visits (Days 0, 1, 2, 3, 7, 14, 28). Visit 1 will be screening and immunisation visit, visits 2 to 7 will be follow-up visits. Blood samples will be taken at every visit.

The study will start after a favourable opinion has been obtained from the Ethics Committee. Written informed consent will be obtained after a subject is informed of the nature, significance, implications and risks of the study and prior to the commencement of any study specific procedures.

10.1 Study Procedures

Visit 1: Screening and immunisation Visit (Day 0)

Subjects will come to CEVAC for VISIT 1 and the procedures listed in Table 1 (Study Procedures Flow Chart) will be performed.

After immunisation, the subject will be observed for 30 minutes. After this period, the subject will be free to leave the Center if he/she's feeling well.

Visits 2, 3, 4 5, 6 and 7: Follow Up Visits

These follow-up visits will occur on specific days relative to immunisation.

A visit window of ± 1 day is acceptable for visits 6 and 7 on days 14 and 28, respectively. However deviations from the proposed schedule should be avoided wherever possible and used only in a situation where a sample would otherwise be lost. Outside of this the visit procedures should still be undertaken and all samples collected, but will be recorded as a protocol deviation. The procedures listed in Table 1 will be performed.

10.2 Duration of Study Participation

Each subject will be participating in the study for 28 days ± 1 day.

10.3 Study Restrictions: prohibited vaccination and medication

Subjects will be required to comply with the following for the duration of the study:

- Subjects must not receive another vaccine within 30 days of visit 1, or at any time during the study period. If a subject receives a non-study vaccine before the end of the study, the subject can continue the study for safety follow-up, but no more blood samples will be collected.
- If a subject uses oral, inhaled, topical or injectable non-steroidal anti-inflammatory drugs or any immunosuppressing or immunomodulating drugs during the course of the study, the subject can continue the study for safety follow-up, but no more blood samples will be collected

11 STUDY MEDICATION

11.1 Treatment Plan

The study medication will be α -RIX-Tetra[®], a quadrivalent inactivated split virus influenza vaccine. The study medication will be supplied as a 0.5 ml pre-filled syringe containing 15 μ g of influenza virus haemagglutinin surface antigens from each of the four virus strains (A/H1N1, A/H3N2, B/Massachusetts and B/Brisbane).

11.2 Preparation, Administration and Dosage of Study Medication

11.2.1 Preparation Instructions

The α -RIX-Tetra[®] vaccine is supplied as pre-filled syringe ready for use.

11.2.2 Route of administration

The vaccine will be administered intramuscularly into the deltoid muscle of the non-dominant arm, according to the SmPC. Alcohol and other disinfecting agents must be allowed to evaporate from the skin before injection of the vaccine since they may inactivate the virus.

11.2.3 Dose and Dosing Schedule

A single 0.5 mL vaccine dose will be administered intramuscularly.

The dose and route selected is that described in the SmPC.

11.3 Packaging and Labelling

Since this study is not blinded, the packaging as provided by the manufacturer will be visible for both participant and study personnel. A secondary label will be added but will not obscure the original label.

11.4 Storage and Accountability of Drug Supplies

The vaccines should be stored at +2°C to +8°C (in a refrigerator).

Simplified accountability records will be kept, to capture the batch number of the product dispensed on a study-specific dispensing form, filed in a study folder to permit retrospective verification if this was necessary.

11.5 Destruction of Clinical Supplies

Any unused vaccines will remain in their original packaging. After study medication accountability has been completed they will be disposed of by discard into the standard clinical waste system.

11.6 Responsibilities

- Trained study nurses will be responsible for ensuring that the vaccine is securely maintained.
- Trained study nurses will be responsible for ensuring that an accurate record of vaccine issued and returned is maintained.
- Vaccine quality issues will be reported to the manufacturer by the PI.

11.7 Compliance

Vaccines will be administered at the clinical site by trained study nurses.

11.8 Treatment Assignment Procedures

Once the informed consent form has been signed and the subject has been found eligible for participation, he/she will be allocated the lowest available subject number. The subject numbers available will be from 01 to 20.

12 STUDY DATA PARAMETERS

12.1 Laboratory Assessments

Blood samples will be collected at the time points specified in Table 1. Safety laboratory tests, including chemistry, haematology, and urinalysis panels, will be performed. For a detailed list, see paragraph 23 and 24. Pregnancy tests will be performed for female subjects at screening, prior to vaccine administration. Blood samples for transcriptomics (PAXgene), humoral (serum) and cellular immune responses (heparinized blood) will be collected at time points specified in the study flow charts.

‘Serum Save’

Several of the parameters being investigated will be analysed in serum. A ‘serum save’ strategy will be used to ensure that enough serum is collected at each time point for each of the required parameters to be measured. The ‘serum save’ strategy applies to the following sample types: acute phase proteins, chemokines and cytokines, serum immunology samples, and ‘biobank’ samples. In practice, when a blood sample is collected the extracted serum will be separated into serum aliquots. These will be stored and made available for analysis during the remaining time in the 5-year Biovacsafe project time period. Serum analyses will be coordinated by Ghent University (Center for Vaccinology). VisMederi laboratory will execute the determination of HAI titres (all 4 strains), the invoice will be sent to CEVAC.

‘Cell Save’

Several of the parameters being investigated will be analysed using PBMC. A ‘cell save’ strategy will be used to ensure that enough cells are collected at selected time points for each of the required parameters to be measured. The ‘cell save’ strategy applies to the following applications: mRNA expression in selected leukocyte populations, antigen-specific cell-mediated immune responses, regulatory T cells, and ‘biobank’ samples. In practice, when a blood sample is collected the extracted PBMC will be separated and divided into several aliquots. These will be stored and made available for analysis during the remaining time in the 5-year Biovacsafe project time period. Cell-mediated immunity analyses will be performed at CEVAC. The global gene expression will be investigated by MPIIB.

Biobank

At every time point a serum sample is required. Enough blood will be collected to extract the required volume of serum for the parameter(s) being measured plus 1ml of additional serum, which will be entered into a biobank. PBMC will be harvested from heparinized blood to examine different aspects of cell-mediated immunity and remaining cells will be entered in the biobank. The biobank will be used to analyse other parameters which become of interest during the study and which would contribute to the aims of the Biovacsafe project. Every effort will be made to collect only the

minimum volume of blood from participants. However, on occasion it is possible that slightly more serum and cells will be extracted from the blood samples than is required. Should this occur, the remaining serum and cells will also be added to the biobank. The creation of the biobank will be managed by CEVAC.

12.1.1 Study Blood Volume

The total volume taken during the study is detailed in Table 2. The total volume taken will be approximately 259.6 ml.

12.1.2 Urinalysis

Urinalysis will be performed by dipstick to evaluate protein, glucose, pH, white and red blood cells. Microscopy may be performed if the dipstick is clinically significant.

12.1.3 Urine pregnancy test

A urine pregnancy test will be done at visit 1 for all female subjects of childbearing potential.

12.2 Vital signs

Vital signs include: diastolic and systolic blood pressure measurement, heart rate and oral temperature. These will be obtained at all study visits.

12.3 Measurement of temperature and injection site reactions

Subjects will be provided with a thermometer to measure the oral temperature on day 0 to day 7 when they wake up and when going to bed. A ruler will be given to measure the largest diameter of local adverse events, namely redness, swelling and induration at injection site. Subjects will also need to register if they experience any local pain. These symptoms will be actively registered from Day 0 to Day 7, in the subject diary cards.

In addition to the local symptoms, subjects will need to register the intensity of a number of general symptoms in the period Day 0 to Day 7, namely headache, fatigue, gastro-intestinal symptoms (nausea, vomiting, diarrhea and/or abdominal pain) and generalised myalgia. This will be recorded in the subject diary cards.

If the subjects experience any other symptoms, they will be instructed to write this down in their diary cards.

The intensity of the symptoms will be graded as following:

0: None

1: Mild: Does not interfere with or prevent normal every day activities.

2: Moderate: Interferes with every day activities, but doesn't prevent the subject from doing them.

3: Severe: Prevents normal every day activities

12.4 Methods and Timing for Assessing and Recording Study Data Parameters

Laboratory safety tests (biochemistry, haematology, urinalysis) will be performed at all study visits. The detailed outline of the study procedures can be found in Table 1 .

Table 2: Volumes of blood collected

Parameter	Day 0 Volume (ml)	Day 1 Volume (ml)	Day 2 Volume (ml)	Day 3 Volume (ml)	Day 7 Volume (ml)	Day 14 Volume (ml)	Day 28 Volume (ml)	Total Volume (ml)
Laboratory safety	12.5	9	9	9	9			48.5
PAXgene (RNA)	7.5	7.5	7.5	7.5				30
Whole blood for PBMC isolation	30	10			30	30		100
Plasma	5.4	5.4	5.4	5.4				21.6
Serum (immunology)	8.5	8.5	8.5	8.5	8.5	8.5	8.5	59.5
TOTAL (ml)	63.9	40.4	30.4	30.4	47.5	38.5	8.5	259.6

13 SAFETY MONITORING

All subjects will receive a study information card that indicates their participation in the study and contact information for the study site.

13.1 Specification of Safety Parameters

13.1.1 Laboratory and Other Safety Assessment Abnormalities Reported as AEs and SAEs

Any abnormal laboratory test results (haematology, biochemistry or urinalysis) or other safety assessments (e.g. vital signs measurements), including those that worsen from baseline, and are felt to be clinically significant in the medical and scientific judgement of the investigator, are to be recorded as AEs or SAEs.

However, any clinically significant safety assessments that are associated with the underlying disease, unless judged by the investigator to be more severe than expected for the subject's condition, are **not** to be reported as AEs or SAEs.

13.1.2 Definition of an AE

- Any untoward medical occurrence in a patient or clinical study subject, to whom a medicinal product has been administered and which does not necessarily have a causal relationship with this treatment.

Note: An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study medication whether or not related to the study medication. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Events meeting the definition of an AE include:

- Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition
- New conditions detected or diagnosed after study medication administration even though it may have been present prior to the start of the study
- Signs, symptoms, or the clinical sequelae of a suspected interaction

- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study medication or a concomitant medication (overdose *per se* will not be reported as an AE/SAE).

Events that **do not** meet the definition of an AE include:

- Medical or surgical procedure (e.g. endoscopy, appendectomy); the condition that leads to the procedure is an AE.
- Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the subject's condition.

13.1.3 Definition of a SAE

An SAE based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for Human Use is any untoward medical occurrence that at any dose:

- (a) results in death;
- (b) is life-threatening;
- (c) requires hospitalisation or prolongation of existing hospitalisation;
- (d) results in persistent or significant disability or incapacity;
- (e) consists of a congenital anomaly or birth defect; or
- (f) is otherwise considered medically significant by the investigator.

13.2 Evaluating and Recording (Serious) Adverse Events

The investigator or designee is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE. These must be recorded in the source adverse event form and CRF.

For all adverse events, the following must be assessed and recorded on the adverse events page of the CRF:

- a) Description of AE
- b) Start date and time
- c) End date and time
- d) Severity i.e. mild, moderate, severe (see below)
- e) Relationship to study medication(s) – completed by clinical research physician
- f) Outcome
- g) Seriousness (see section on Serious Adverse Events)

Subjects will be kept under observation for 30 minutes after vaccination to ensure their safety.

All AEs starting within 28 days following vaccination must be recorded into the appropriate section of the CRF, irrespective of intensity or whether or not they are considered vaccination-related.

The time period for collecting and recording SAEs will begin at the receipt of study vaccine and will end at Day 28 (study end).

An overview of the protocol-required reporting periods for AEs, SAEs, and pregnancies is given in Table 3.

SAEs that are spontaneously reported by a subject to the investigator after study completion and considered by the investigator to be caused by the study medication with a reasonable possibility should be handled in the same manner as for SAEs reported during the study.

In the event of unexplained clinically abnormal laboratory test values, the tests should be repeated immediately and followed up until the results have returned to within the range of normal and/or an adequate explanation of the abnormality is given.

Table 3: Reporting periods for adverse events, serious adverse events and pregnancies

Study activity	Vaccination						Study conclusion
	(Visit 1)	(Visit 2)	(Visit 3)	(Visit 4)	(Visit 5)	(Visit 6)	(Visit 7)
Timing of reporting	Day 0	Day 1	Day 2	Day 3	Day 7	Day 14	Day 28
Reporting of solicited AEs							
Reporting of Unsolicited AEs							
All SAEs							
Reporting of pregnancies							

13.3 Intensity of Event

The intensity of an adverse event is defined as follows:

- Mild** Transient symptoms, requiring no treatment, no interference with subject's daily activities, easily tolerated.
- Moderate** Marked symptoms, moderate interference with the subject's daily activities, usually ameliorated by simple therapeutic measures.
- Severe** Considerable interference with the subject's daily activities, requires intensive therapeutic intervention, incapacitating.

The term **severe** is a measure of **intensity**: thus a severe AE is not necessarily **serious**. For example, nausea of several hours duration may be rated as severe, but may not be clinically serious.

13.4 Relationship to study product

The relationship of each adverse event to the study medication must be recorded by a medically qualified member of staff as one of the following scale:

Definitely Not related The AE is judged to be clearly and incontrovertibly due only to extraneous causes (for example, disease, environment) definitely not associated with the test drug being given and does not meet the criteria for any other drug relationship listed.

Probably Not related In general, this category is applicable to an AE which meets the following criteria (it certainly must meet the first two criteria):

1. It does not follow a reasonable temporal sequence from the drug administration.
2. It may readily have been produced by the subject's clinical state, environmental or toxic factors, or other modes of therapy administered to the subject.
3. It does not follow a known pattern of response to the suspected drug.
4. It does not reappear or worsen when the drug is re-administered.

Possibly Related This category applies to those AEs in which the connection with the test drug administration appears unlikely but cannot be ruled out with certainty. An AE may be considered as possibly drug related if, or when:

1. It follows a reasonable temporal sequence from administration of the drug.
2. It may have been produced by the subject's clinical state, environmental or toxic factors or other modes of therapy administered to the subject.
3. It follows a known pattern of response to the suspected drug.

Probably Related This category applies to those AEs which are considered, with a high degree of certainty, to be related to the test drug. An AE may be considered as probably drug related if:

1. It follows a reasonable temporal sequence from administration of the drug.
2. It cannot be reasonably explained by the known characteristics of the subject's clinical state, environmental or toxic factors, or other modes.
3. It disappears or decreases on cessation or reduction in dose (there are important exceptions when an AE does not disappear upon discontinuation of the drug, yet drug-relatedness clearly exists).
4. It follows a known pattern of response to the suspected drug.

5. It reappears upon re-challenge.

Definitely Related This category applies to those AEs which are considered to be definitely related to the test drug. An AE may be considered as

Definitely related if:

1. There is evidence of exposure to the test drug.
2. It follows a reasonable temporal sequence from administration of the drug.
3. It cannot be reasonably explained by the known characteristics of the subject's clinical state, environmental or toxic factors, or other modes.
4. The AE is more likely explained by the test drug than by any other cause.
5. De-challenge is positive.
6. Re-challenge (if feasible) is positive.
7. The AE shows a pattern consistent with previous knowledge of the test drug or test drug class.

13.5 Expectedness of SAEs

For this study, an adverse reaction is 'unexpected' if its nature and severity are not consistent with the information about the study medication in question, set out in the SmPC. A medically qualified member of staff must assign expectedness.

13.6 Reporting of serious adverse events, pregnancies, and other events

All SAEs and pregnancies occurring during clinical trials must be reported by the Investigator within 2 working days after becoming aware of the SAE to:

- The local Ethic Committee (EC)
- Bimetra Clinics of the University Hospital Ghent

This reporting is done by using the appropriate SAE form. For the contact details, see below.

In case the investigator decides the SAE is a Suspected Unexpected Serious Adverse Reaction (SUSAR), Bimetra Clinics will report the SUSAR to the Central EC and the competent authorities (CA) within the timelines as defined in national legislation.

In case of a life-threatening SUSAR the entire reporting process must be completed within 7 calendar days. In case of a non life-threatening SUSAR the reporting process must be completed within 15 calendar days.

The first report of a SAE may be made by telephone, e-mail or facsimile (FAX).

Contact details of Bimetra Clinics:

e-mail: bimetra.clinics@uzgent.be

tel.: +32 9 332 05 00

fax: +32 9 332 05 20

The investigator must provide the minimal information: i.e. trial number, subject's initials and date of birth, medication code number, period of intake, nature of the AE and investigator's attribution.

This report of a SAE by telephone must always be confirmed by a written, more detailed report. For this purpose the appropriate SAE form will be used. Pregnancies occurring during clinical trials are considered immediately reportable events. They must be reported as soon as possible using the same SAE form. The outcome of the pregnancy must also be reported.

14 STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN

14.1 Responsibility for Analysis

The analysis of the data obtained from this study will be the responsibility of the BioVacSafe consortium. Additional integrated systems biology analysis may be undertaken by specialist laboratories and collaborators.

14.2 Justification of Sample Size

This study is designed to specifically complement the read-outs from a controlled influenza virus infection challenge study conducted at Imperial College London. To compare the data generated during this clinical vaccine trial with those generated during the challenge study, a comparable cohort of healthy young adults is preferred. The sample size in this study is 20.

14.3 Definition of Study Completion

Study completion is defined as the date the last subject completes the final visit in the study.

14.4 Definition of Criteria for Termination of the Study

Study termination is defined as a permanent discontinuation of the study due to unanticipated concerns of safety to the study subjects arising from AEs recorded during the study that are definitely related to the protocol, and are not present in the SmPC; or availability of other new data (pharmacokinetic, pharmacodynamic, efficacy, biologic etc.) arising from clinical or preclinical studies with this study drug. A study may be paused during review of newly available preclinical/clinical safety, pharmacokinetic, pharmacodynamic, efficacy, or biologic data, or other issues of interest or potential concern prior to a final decision for continuation or termination of the study.

14.5 Analysis of Clinical Events and Exploratory Endpoints after immunisation

All subjects who receive a dose of study medication will be included.

All AEs will be coded using MedDRA prior to database lock. Adverse events will be analysed, irrespective of their causal relationship, by treatment group. The terms mentioned in the tabulations will be the MedDRA organ system and preferred terms.

For Serious Adverse Events meeting the definition of section 13.1, tabulations will be provided with the number of subjects exposed, the number of subjects with at least one Serious Adverse Event, the number of subjects with at least one Serious Adverse Event by organ system and preferred term. Separate tables will be provided, if relevant, for SAEs leading to withdrawal from study.

15 STUDY DOCUMENTATION ADMINISTRATION

15.1 Source documents and eCRF

All evaluations that are reported in the eCRF must be supported by appropriately signed identified source documentation.

Paper workbooks are provided for each subject, and all data related to the study will be recorded in these workbooks. These source documents are to be completed at the time of the subject's visit so that they always reflect the latest observations on the subjects.

The investigator must verify that all data entries in the workbooks are accurate and correct by signing the relevant pages. If certain information is not available, not applicable, not done or unknown, the clinical staff or investigator will enter the relevant abbreviation, i.e. NA to confirm that the data field has not been overlooked.

This also applies to subjects who fail to complete the study. If a subject withdraws from the study, the reason (if known) must be noted on the workbook. If a subject is withdrawn from the study because of a treatment-limiting adverse event, thorough efforts should be made clearly to document the outcome.

All forms should be typed or filled out using a black ball-point pen, and must be legible. All entries, corrections and alterations are to be made by the responsible investigator or her/his designee. With the exception of obvious mistakes, the corrections need to be commented. Corrections should be made in such a way that the original entry is not obscured. The corrected data should be entered, dated, and initialled by the investigator or his designee.

The information recorded in the paper workbooks will be transcribed into the eCRF following the subjects visit and within 3 working days.

15.2 Monitoring

Monitoring will be performed by Bimetra Clinics in accordance with applicable regulations and standards of GCP.

When reviewing data collection procedures, discussion will include identification, agreement and documentation of data items for which the workbook will serve as the source document.

The monitor will review the workbooks/eCRFs, evaluate them for accuracy (including source data verification) and completeness, and return all forms with missing information and/or errors to the clinical staff or investigator for correction.

The monitor will supervise the study to ensure that the:

- Data are authentic, accurate, and complete
- Safety and rights of subjects are being protected
- Study is conducted in accordance with the currently approved protocol and any other study agreements, GCP and all applicable regulatory requirements

15.3 Access to Source Data Documents

The investigator will permit trial-related monitoring, audits, IRB/IEC review, and regulatory inspections by providing direct access to source data/documents.

15.4 Data Handling and Record Retention

The investigator must maintain adequate records to enable the conduct of the study to be fully documented. The investigator should arrange for retention of the essential documents in the investigator's Trial Master File for at least fifteen years after the final study report has been signed.

15.5 Subject Confidentiality and Data Protection

The investigator must ensure that subject's anonymity will be maintained. On eCRFs or other documents and blood/urine samples, subjects should **not** be identified by their names, but by a subject number. The investigator should keep a separate enrolment log showing subject numbers, names and date of birth. Documents such as subjects' separate written consent forms should be maintained by the investigator in strict confidence.

16 QUALITY CONTROL AND QUALITY ASSURANCE

To ensure compliance with GCP and all applicable regulatory requirements, the sponsor may conduct a quality assurance audit of the site records, and the regulatory agencies may conduct a regulatory inspection at any time during or after completion of the study. In the event of an audit or inspection, the investigator (and institution) must agree to grant the auditor(s) and inspector(s) direct access to all relevant documents and to allocate their time and the time of their staff to discuss any findings/relevant issues.

A study monitor from Bimetra Clinics is responsible for visiting the institution at regular intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to ICH GCP and local regulations on the conduct of clinical research. The monitor is responsible for inspecting the workbooks/eCRFs and ensuring completeness of the study essential documents. The monitor should have access to subject medical records and other study-related records needed to verify the entries on the workbooks/eCRFs. The monitor will communicate deviations from the protocol, SOPs, GCP and applicable regulations to the investigator and will ensure that appropriate action designed to prevent recurrence of the detected deviations is taken and documented. The investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are addressed and documented.

17 CLINICAL STUDY PROTOCOL DEVIATIONS AND AMENDMENTS

Any 'substantial' protocol amendment(s) (meaning that it could have a significant impact on the safety or physical or mental integrity of the subjects, the scientific value of the study, the conduct or management of the study, the quality or the safety of any study vaccines used in the study) must be submitted to the Independent Ethics Committee (IEC) prior to its implementation.

Amendments to exploratory endpoints, objectives, parameters and variables will not be considered substantial.

For non-substantial changes that do not affect safety or study validity e.g. an administrative change, the IEC is not required to be notified. Non-substantial amendments will be reported to the IEC at the time of a subsequent substantial amendment.

In the case of changes consisting of urgent safety measures to protect the study subjects, the sponsor should inform the IEC as soon as possible after these measures have been implemented.

18 CONDITIONS FOR TERMINATING THE STUDY

Study completion is defined as the date the last subject completes the final visit in the study. Study termination is defined in section 10.2.

If, in the opinion of the investigator, the clinical observations or pharmacokinetic profiles in the study suggest that it may be unwise to continue, the investigator may terminate part of, or the entire study, after consultation with the sponsor, or the sponsor may terminate part of, or the entire study, for safety or administrative reasons. A written statement fully documenting the reasons for such termination will be provided to the IEC.

19 ETHICAL AND REGULATORY REQUIREMENTS

The trial will be conducted in compliance with the protocol, principles of GCP, Data Protection Act and other regulatory requirements, as appropriate, and will abide by the principles of the 2013 revision of the Declaration of Helsinki.

19.1 Informed Consent

It is the responsibility of the investigator to obtain written informed consent from each subject participating in this study, after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study. This includes obtaining the appropriate signatures and dates on the informed consent document prior to the performance of any study specific procedures. Subjects will be given written information outlining the study details given approval by the IEC. Any changes to the approved version of the information sheet/consent form must be approved by the IEC prior to its implementation, unless it is for urgent safety measures. A copy of the signed consent form will need to be given to the subject.

The investigator, or person under his responsibility, must also explain that the subject is completely free to refuse to enter the study or to withdraw from it at any time. The CRF for this study contains a section for documenting informed consent, and the investigator, or person under his responsibility, must complete it appropriately.

19.2 Independent Ethics Committee (IEC)

This protocol and any accompanying material provided to the subjects (such as the information sheet and consent form) will be submitted by the investigator, or person under his responsibility, to the appropriate IEC. Approval from the committee must be obtained in writing before starting the study and the approval letter must reference which documents were reviewed and approved.

Any required changes will be forwarded to the IEC for their approval. Written approval of the revised documents should also be obtained from the IEC. Depending upon the exact changes, written approval of the revised documents may not be required prior to the commencement of the screening process.

The IEC must provide a copy of their membership list, and a list of names of those members reviewing the study. All documents related to IEC correspondence will be kept at CEVAC.

19.3 Final Reports

The sponsor will notify the IEC within 90 days of the end of the study. If the study is terminated prematurely, this reporting timeframe will be reduced to 15 days from the termination of the study.

The study report will be provided to the IEC within one year of completion of the study.

20 FINANCE AND INSURANCE

The sponsor, Ghent University Hospital - CEVAC, maintains an insurance to cover its liability or the liability of any person involved in the conduct of the study, in accordance with the requirements of the Belgian law dated 07 May 2004.

21 PUBLICATIONS

Before recruitment the trial will be registered with clinicaltrials.gov (<http://clinicaltrials.gov/>) website.

All publications and communications arising from this trial will comply with the Project and Grant Agreements for the Innovative Medicines Initiative project BIOVACSAFE proposal number 115308.

22 REFERENCES

Pulendran, B, Li, S and Nakaya, HI (2010). Systems vaccinology. *Immunity*, 33, 516 – 29.

Querec, TD, Akondy, RS, Lee, EK, Cao, W, Nakaya, HI, Teuwen, D, Pirani, A, Gernert, K, Deng, J, Marzolf, B, Kennedy, K, Wu, H, Bennouna, S, Oluoch, H, Miller, J, Vencio, RZ, Mulligan, M, Aderem A, Ahmed, R, Pulendran, B (2009). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. *Nat Immunol*, 10, 116 – 25.

Vahey, MT, Wang, Z, Kester, KE, Cummings, J, Heppner, DG Jr, Nau, ME, Ofori-Anyinam, O, Cohen, J, Coche, T, Ballou, WR, Ockenhouse, CF (2010). Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS, S malaria vaccine. *J Infect Dis*, 15, 580 – 9.

23 Laboratory Safety Analysis.

BLOOD	ESR White blood cell count Haemoglobin Platelets Red blood cell Haematocrit MCV MCH MCHC RDW neutrophils lymphocytes monocytes eosinophils basophils creatinine eGFR albumin CRP (standard method – lower sensitivity) CRP (high sensitivity method) ALT AST GGT total protein
URINE	Urine dipstick analysis: glucose protein WBC bilirubin bacteria

24 Exploratory analyses

Negative acute-phase proteins

Transferrin

Positive acute-phase proteins

D-dimer protein

Mannose-binding protein

Alpha-1-antitrypsin

Alpha-1-acid glycoprotein (orosomucoid)

Alpha-2-macroglobulin

Fibrinogen

Prothrombin

Factor VIII
von-Willebrand factor (Ag)
Complement factor (C3)
Ferritin
Ceruloplasmin (Cp)
Haptoglobin (Hp)
(Serum Amyloid A)
(Serum Amyloid P complement)

